查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1561471

2024-2032 年按產品類型、給藥途徑、疾病、應用和地區分類的疫苗佐劑市場報告

Vaccine Adjuvants Market Report by Product Type, Route of Administration, Diseases, Application, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2023年全球疫苗佐劑市場IMARC Group達9.965億美元。由於傳染病發病率上升、免疫學和疫苗技術的重大里程碑、對罕見疾病的認知不斷提高、未建成人口對大流行疫苗接種工作的興趣增加、政府支出迅速成長以及需求增加，全球疫苗佐劑市場正在快速成長。

疫苗佐劑市場分析：

  • 主要市場促進因素：基於多種因素，疫苗佐劑市場前景正在擴大，例如全球範圍內越來越重視個人化醫療，根據每個人獨特的免疫需求調整疫苗配方，推動疫苗佐劑市場擴大的很大一部分佔有率。此外，生物資訊學和系統生物學的新技術使人們對免疫反應有了更深入的了解，並隨後改進了佐劑設計，大大滿足了疫苗佐劑市場的需求。除此之外，隨著癌症和阿茲海默症等慢性疾病治療性疫苗的大量湧入，為擴大佐劑的應用開闢了一條重要途徑，再加上抗生素抗藥性的增加，需要開發更強大的疫苗，這進一步推動了佐劑的發展。眾多的環境變化和不斷上升的病原體威脅也導致了動態變化，促進了對佐劑不斷創新的需求。
  • 主要市場趨勢：疫苗佐劑市場的主要趨勢包括轉向合成和分子確定的佐劑，作為增強佐劑安全性和有效性的手段。影響疫苗佐劑市場佔有率的另一個因素是向可以刺激體液和細胞免疫的佐劑系統發展，這種方法認知到此類條件和治療的多種複雜性，並轉化為先進的疫苗佐劑市場預測。人們對黏膜疫苗的興趣也在成長，因為這些疫苗透過針對感染源位點提供更全面的保護。永續且經濟可行的生產是另一個趨勢，這是疫苗佐劑市場未來的關鍵組成部分。
  • 地理趨勢：目前，疫苗佐劑市場概況的全球領導者是北美，其憑藉強大的醫療基礎設施和研發（R＆D）資金，使其成為全球領先者。此外，在大型製藥公司的存在和領先研究機構的創新的支持下，公眾的高度認知提高了疫苗佐劑的市場價格。因此，大多數疫苗佐劑市場統計數據體現在安全性的提高、功效的提高和成本的降低。由於醫療保健支出不斷增加以及人們對疫苗可預防疾病的認知不斷增加，歐洲和亞太地區潛力最大。
  • 競爭格局：疫苗佐劑產業的一些主要市場參與者包括 Adjuvatis、Agenus Inc.、Croda International Plc、CSL Limited、Dynavax Technologies、InvivoGen、Novavax Inc.、OZ Biosciences、Phibro Animal Health Corporation、SEPPIC、SPI Pharma、 ETC 。
  • 挑戰與機會：疫苗佐劑市場最重大的挑戰是與廣泛的臨床試驗和測試相關的監管和安全問題，以證明佐劑的功效和可能的健康風險。然而，展望未來，這在不同方面都是一個機會。 COVID-19大流行增加了疫苗佐劑市場的投資。因此，疫苗佐劑市場分析持續成長，探索新型佐劑以徹底改變疫苗設計，提升全球健康安全性。

疫苗佐劑市場趨勢：

疫苗和免疫學技術的進步

免疫學在疫苗佐劑的開發方面取得了重大進展，新佐劑比以前想像的更有效、更安全。技術進步使得能夠設計出能夠選擇性增強對抗原的免疫反應的佐劑，從而顯著提高疫苗對抗世界各地多種病原體的能力。最近，2024 年 2 月，艾伯維 (AbbVie) 和 Tentarix Biotherapeutics 宣佈建立多年戰略合作夥伴關係，共同開發腫瘤學和免疫學領域的生物候選藥物。該協議價值超過6400萬美元。候選藥物的開發將結合艾伯維在腫瘤學和免疫學方面的能力與 Tentarix 的專有 Tentacles 平台，以發現和開發針對每個醫學分支中的一個靶標的有條件活性的多特異性生物製劑。這將激活可以調節疾病途徑的免疫細胞，同時減少通常與非特異性治療相關的安全問題。

對罕見疾病的認知與理解不斷提高

對罕見疾病的日益認知加速了疫苗開發的獨特挑戰。這種新的認知激起了人們對可以根據不同利益相關者的具體需求進行客製化的疫苗佐劑的興趣。至於歐盟，他們將 RD 定義為歐洲人口中每 10 萬人中受影響人數少於 50 人。然而，美國門診孤兒藥法案將 RD 定義為影響美國不到 20 萬人。其他定義包括剛果每 10 萬人中低至 5 人，而印度最高為每 10 萬人中 76 人。平均而言，全球每 10 萬人中就有 40 人受到 RD 影響。最近，根據 3,585 個 RD，罕見病患病率佔世界人口的 3.5% 至 5.9%，相當於 263 至 4.46 億人。

全球推動疫苗接種以應對流行病威脅

以新冠肺炎 (COVID-19) 為代表的對抗流行病威脅的鬥爭引發了一場史無前例的全球疫苗接種運動，推動疫苗佐劑市場成為優先公共衛生問題的焦點。此外，疫苗佐劑的主要用途是增強免疫反應、疫苗穩定性、提高疫苗效率和減少疫苗劑量，進而推動市場成長。 「根據ABC 新聞報道，每週新增15,141 例因COVID-19 入院的病例。根據美國疾病控制與預防中心(CDC) 的資訊，這與2024 年4 月初的情況大致相同。但並不像以前那麼高。根據美國疾病管制與預防中心 (CDC) 通報，在新冠病毒大流行期間，總共有超過 600 萬美國人住院治療。

疫苗佐劑市場區隔：

IMARC Group提供了每個細分市場的主要趨勢的分析，以及 2024-2032 年全球、區域和國家層面的預測。我們的報告根據產品類型、給藥途徑、疾病和應用對市場進行了分類。

按產品類型分類：

  • 佐劑乳劑
  • 病原體成分
  • 顆粒佐劑
  • 組合佐劑
  • 其他

助劑乳液佔據大部分市場佔有率

該報告根據產品類型對市場進行了詳細的細分和分析。這包括佐劑乳液、病原體成分、顆粒佐劑、組合佐劑等。根據該報告，佐劑乳液代表了最大的部分。

佐劑乳劑細分市場的推動因素是對具有增強功效和更持久免疫力的疫苗的需求不斷成長。這種興趣源於乳劑佐劑能夠激發強烈而廣泛的免疫反應，使其成為流感和 COVID-19 等複雜疾病的疫苗的理想選擇。乳劑佐劑的多功能性與多種抗原相容，進一步增強了它們的吸引力。此外，奈米技術的進步改進了這些佐劑的遞送機制，提高了它們的有效性，同時保持了安全性。旨在最佳化乳劑配方的持續研究和開發工作對於滿足不斷成長的疫苗佐劑市場需求至關重要，強調了它們在未來疫苗開發策略中的關鍵作用。

依給藥途徑分類：

  • 口服
  • 肌肉注射
  • 鼻內
  • 皮下
  • 皮內
  • 其他

肌肉注射代表領先的細分市場

該報告根據給藥途徑對市場進行了詳細的細分和分析。這包括口服、肌肉內、鼻內、皮下、皮內等。根據該報告，肌肉注射佔最大部分。

肌肉注射細分市場的推動因素是對需要深入組織滲透才能獲得最佳功效的疫苗的需求不斷成長，例如針對流感、破傷風和 COVID-19 的疫苗。這種方法之所以受到青睞，是因為它能夠將大量疫苗直接輸送到血液供應豐富的肌肉中，促進更強、更快的免疫反應。此外，與其他方法相比，肌肉注射途徑因其給藥相對方便、不適感最小且不良反應風險較低而受到青睞，使其成為全球疫苗接種計劃中廣泛接受的做法。疫苗吸收率的一致性和支持其有效性的廣泛歷史資料進一步促進了其採用，突顯了該領域的成長。

依疾病分類：

  • 癌症
  • 傳染病
  • 其他

傳染病佔大部分市場佔有率

該報告根據疾病提供了詳細的市場細分和分析。這包括癌症、傳染病等。報告稱，傳染病佔最大部分。

傳染病領域是由全球流行病日益流行和新出現的傳染病威脅所推動的，這凸顯了對有效疫苗的迫切需求。國際旅行、都市化和氣候變遷等因素導致傳染病的傳播，因此需要快速開發和部署含有強效佐劑的疫苗。政府和國際對抗傳染病的舉措以及對研發的大量投資進一步推動了該領域的成長。此外，公眾意識和醫療基礎設施的改善在支持疫苗接種計劃方面發揮著重要作用，從而增加了對有效對抗這些疾病的創新疫苗佐劑的需求。

按應用分類：

  • 研究
  • 商業的

研究代表了領先的細分市場

該報告根據應用程式提供了詳細的市場細分和分析。這包括研究和商業。根據該報告，研究代表了最大的部分。

疫苗佐劑市場的研究領域受到對針對更廣泛病原體（包括新出現和重新出現的傳染病）的更有效疫苗的需求不斷成長的推動。這種需求加上對免疫系統複雜性的日益了解，促使科學家探索能夠引發更強、更持久免疫反應的新型佐劑配方。此外，針對個人基因組成的個人化醫療和疫苗的推動推動了對創新佐劑的探索。生物技術和奈米技術的進步進一步推動了這一領域的發展，使得能夠開發出可以精確設計的下一代佐劑，以提高疫苗的有效性，同時最大限度地減少副作用。

按地區分類：

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

北美市場領先，佔據最大的疫苗佐劑市場佔有率

該報告還對所有主要區域市場進行了全面分析，其中包括北美（美國和加拿大）；歐洲（德國、法國、英國、義大利、西班牙、俄羅斯等）；亞太地區（中國、日本、印度、韓國、澳洲、印尼等）；拉丁美洲（巴西、墨西哥等）；以及中東和非洲。報告稱，北美是疫苗佐劑最大的區域市場。

由於對疫苗研發（R＆D）的大量投資，北美的疫苗佐劑預計將主導市場，這些疫苗旨在解決各種傳染病以及公共和私營部門日益成長的健康問題。該地區具有疫苗核准流程快速的優勢，這鼓勵製藥公司擴大和增加對輔助技術的投資。此外，北美擁有許多頂尖研究中心的優勢，與生物技術領域的合作頻繁。因此，它是醫療技術和創新領域。此外，為了提高疫苗的有效性，佐劑的使用擴大認知到提高疫苗的有效性和安全性的重要性，從而推動了北美市場的擴張。

（請注意，這只是關鍵參與者的部分列表，報告中提供了完整列表。）

  • 疫苗佐劑市場的主要參與者正在積極參與研發活動，以推出創新且更有效的佐劑配方。這些努力旨在增強疫苗引起的免疫反應，確保針對各種傳染病以及癌症等慢性病的治療性疫苗提供更廣泛和更持久的保護。例如，2022 年 2 月，Novavax Inc. 宣布了其 3 期臨床試驗的積極中期結果，該試驗評估了其 COVID-19 候選疫苗 NVX-CoV2373 與其專有佐劑 Matrix-M 的結合。結果顯示對 COVID-19 具有很強的功效，整體療效超過 90%。合作和夥伴關係是一項共同策略，共同學術機構、研究組織和生物技術公司的專業知識，加速下一代佐劑的開發。此外，這些公司正在投資先進技術並探索新型佐劑物質，包括合成分子和天然化合物，以提高疫苗功效和安全性。隨著公司在複雜的環境中將其創新推向市場，監管合規性和追求快速核准流程也至關重要。透過這些行動，主要參與者為全球疫苗佐劑市場的動態成長和發展做出了重大貢獻。

疫苗佐劑市場新聞：

  • 2022 年 9 月：Dynavax Technologies 開始了一項重大努力，開始對其 COVID-19 候選疫苗 DVX-COV2373 進行 2 期臨床試驗。該疫苗採用該公司專有的佐劑 CpG 1018 配製而成，為持​​續對抗 COVID-19 大流行提供了一條有希望的途徑。該試驗的獨特之處在於其與流行病防範創新聯盟（CEPI）的合作，該聯盟是一個全球合作夥伴關係，專注於加速針對新出現傳染病的疫苗的開發。這項 2 期試驗的主要目標是擴展早期發現並評估 DVX-COV2373 在更大人群中的安全性和有效性。這一步驟對於確保疫苗符合嚴格的監管標準，同時衡量其在不同人群中的表現至關重要。
  • 2024 年2 月：CSL（ASX：CSL；USOTC：CSLLY）發表了AEGIS-II 3 期試驗的主要結果，該試驗評估了CSL112（載脂蛋白AI [人類]）與安慰劑相比在降低重大疾病風險方面的有效性與安全性。

本報告回答的關鍵問題

  • 2023年全球疫苗佐劑市場規模是多少
  • 2024-2032年全球疫苗佐劑市場預計成長率是多少
  • 推動全球疫苗佐劑市場的關鍵因素是什麼
  • COVID-19對全球疫苗佐劑市場有何影響
  • 根據產品類型，全球疫苗佐劑市場的細分如何
  • 根據給藥途徑，全球疫苗佐劑市場的細分如何
  • 全球疫苗佐劑市場按疾病分類是怎樣的
  • 基於應用的全球疫苗佐劑市場區隔是怎樣的
  • 全球疫苗佐劑市場的重點區域有哪些
  • 10. 全球疫苗佐劑市場的主要參與者/公司有哪些？

本報告回答的關鍵問題

  • 2023年全球疫苗佐劑市場規模有多大？ 2024-2032年全球疫苗佐劑市場的預期成長率是多少？
  • 推動全球疫苗佐劑市場的關鍵因素是什麼？
  • COVID-19對全球疫苗佐劑市場有何影響？
  • 根據產品類型，全球疫苗佐劑市場的細分如何？
  • 根據給藥途徑，全球疫苗佐劑市場的細分如何？
  • 根據疾病的不同，全球疫苗佐劑市場的細分如何？
  • 根據應用，全球疫苗佐劑市場的細分如何？
  • 全球疫苗佐劑市場的重點區域有哪些？
  • 全球疫苗佐劑市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球疫苗佐劑市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依產品類型

  • 佐劑乳劑
    • 市場趨勢
    • 市場預測
  • 病原體成分
    • 市場趨勢
    • 市場預測
  • 顆粒佐劑
    • 市場趨勢
    • 市場預測
  • 組合佐劑
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依管理途徑

  • 口服
    • 市場趨勢
    • 市場預測
  • 肌肉注射
    • 市場趨勢
    • 市場預測
  • 鼻內
    • 市場趨勢
    • 市場預測
  • 皮下
    • 市場趨勢
    • 市場預測
  • 皮內
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：依疾病分類

  • 癌症
    • 市場趨勢
    • 市場預測
  • 傳染病
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：按應用

  • 研究
    • 市場趨勢
    • 市場預測
  • 商業的
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 11 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 14 章：價格分析

第15章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Adjuvatis
    • Agenus Inc.
    • Croda International Plc
    • CSL Limited
    • Dynavax Technologies
    • InvivoGen
    • Novavax Inc.
    • OZ Biosciences
    • Phibro Animal Health Corporation
    • SEPPIC
    • SPI Pharma
Product Code: SR112024A4385

The global vaccine adjuvants market size reached US$ 996.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,639.3 Million by 2032, exhibiting a growth rate (CAGR) of 11.1% during 2024-2032. Global vaccine adjuvants market is growing rapidly due to the rising incidence of infectious diseases, significant milestones in immunology and vaccine technology, the escalating awareness of rare disease, the increased interest in pandemic vaccination efforts among the unbuilt population, burgeoning government spending, and the need for effective vaccination for the elderly.

Vaccine Adjuvants Market Analysis:

  • Major Market Drivers: The vaccine adjuvants market outlook is expanding based on various factors, such as growing emphasis on personalized medicine taking place globally adjusts vaccine formulations to the unique immunological needs of each individual, driving a large share of the vaccine adjuvants market expansion. Moreover, novel technologies in bioinformatics and systems biology have led to a deeper understanding of immune responses and subsequent refinement in adjuvant design, contributing considerably to the vaccine adjuvants market demand. Apart from this, with the influx of therapeutic vaccines for chronic diseases such as cancer and Alzheimer's, a significant avenue has been opened to expand the adjuvant's application, supplemented by the rise in antibiotic resistance that demands the development of more robust vaccines, which is further propelling the vaccine adjuvants market growth. There have also been numerous environmental changes and rising pathogen threats that contribute to dynamic changes, promoting the need for constant adjuvant innovation.
  • Key Market Trends: The key vaccine adjuvants market trends include to shift to synthetic and molecularly defined adjuvants as a means of enhancing the safety and efficacy profile of adjuvants. Another factor contributing to the vaccine adjuvants market share is the move towards adjuvant systems that can stimulate both humoral and cellular immunity as an approach that recognizes the multiple levels of complexity in such conditions and treatments and translates into an advanced vaccine adjuvants market forecast. The interest in mucosal vaccines has also grown, as these vaccines offer more comprehensive protection by targeting the origin site of infection. Sustainable and economically feasible production is another trend, which is a critical component for the future of vaccine adjuvants market.
  • Geographical Trends: Currently, the global leader in vaccine adjuvants market overview is North America based on robust healthcare infrastructure and research and development (R&D) funding, making it a global leader. Moreover, high public awareness has increased the vaccine adjuvants market price supported by presence of large pharmaceuticals and innovation from leading research institutes. Hence, the most vaccine adjuvants market statistics are expressed in the improved safety profiles, efficacy improvements, and cost reductions. European and Asia-Pacific regions hold the highest potential due to rising healthcare spending and awareness of vaccine-preventable diseases.
  • Competitive Landscape: Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.
  • Challenges and Opportunities: The most significant challenge in the vaccine adjuvants market is the regulatory and safety issues associated with extensive clinical trial and testing to prove the adjuvants' efficacy and possible health risks. However, promising the future, it's an opportunity in different aspects. The COVID-19 pandemic has surged the investments in the vaccine adjuvants market. As a result, the vaccine adjuvants market analysis continues to grow, exploring novel adjuvants to revolutionize vaccine design densifies the global health safety.

Vaccine Adjuvants Market Trends:

Advancements in Vaccine and Immunology Technology

Immunology has made significant strides in vaccine adjuvant development, with new adjuvants being both more effective and safer than previously thought. Technological progress allows to design adjuvants that can selectively increase immune response to an antigen, which significantly increased vaccines' capability to fight a wide range of pathogens around the world. Recently, in February 2024, AbbVie , and Tentarix Biotherapeutics revealed the multi-year strategic partnership to develop biologic candidates in oncology and immunology. The agreement is valued more than USD 64 million. The drug candidates will be developed to combine AbbVie's capabilities in oncology and immunology with Tentarix's proprietary Tentacles platform to discover and develop conditionally active, multi-specific biologics against one target in each branch of medicine. This will activate immune cells that can modulate disease pathways while reducing the safety concern, typically associated with non-specific treatment.

Rising Awareness and Understanding of Rare Diseases

The growing recognition for rare diseases has accelerated distinctive challenges in the vaccine development. This new awareness has piqued the interest in vaccine adjuvants that can be customized to the specific needs of various stakeholders. As regards to the European Union, they defined RDs as affecting less than 50 per 100,000 people in the European population. However, the American Orphan Drug Act, outpatient, defined RDs as affecting less than 200,000 people in the United States. Other definitions included one as low as 5 per 100,000 people in Congo, while the highest was 76 per 100,000 people in India . On average, RDs affects 40 in every 100,000 people in the world. Recently, the prevalence of Rare Diseases prevalence, based on 3,585 RDs, was between 3.5 to 5.9 percent of the world population, equaling 263 to 446 million individuals.

Global Push for Vaccinations Against Pandemic Threats

The fight against the threat of pandemics, exemplified by COVID-19, sparked an unprecedented global vaccination crusade, propelling the vaccine adjuvants market into the spotlight of priority public health concerns. Moreover, the key uses of vaccine adjuvants are enhancing immune response, vaccine stability, improving vaccine efficiency and reducing vaccines doses, which in turn is propelling the market growth. "There were 15,141 new weekly hospital admissions for COVID-19, according to the ABC news. That's about the same as in early April 2024, according to information from the Centers for Disease Control and Prevention (CDC). But it's not as high as the peak of 150,650 hospitalizations per week for the week of Jan. 22, 2022, during the omicron wave". In total, more than 6 million Americans have been hospitalized over the course of the pandemic, the CDC reports.

Vaccine Adjuvants Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product type, route of administration, diseases, and application.

Breakup by Product Type:

  • Adjuvant Emulsions
  • Pathogen Components
  • Particulate Adjuvants
  • Combination Adjuvants
  • Others

Adjuvant Emulsions accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product type. This includes adjuvant emulsions, pathogen components, particulate adjuvants, combination adjuvants, and others. According to the report, adjuvant emulsions represented the largest segment.

The adjuvant emulsions segment is driven by the increasing demand for vaccines with enhanced efficacy and longer-lasting immunity. This interest stems from the ability of emulsion-based adjuvants to provoke a strong and broad immune response, making them ideal for use in vaccines against complex diseases such as influenza and COVID-19. The versatility of emulsion adjuvants, compatible with a wide range of antigens, further boosts their appeal. Additionally, advancements in nanotechnology have improved the delivery mechanisms of these adjuvants, increased their effectiveness while maintaining safety profiles. The ongoing research and development efforts aimed at optimizing emulsion formulations are crucial in meeting the growing vaccine adjuvants market demand, underscoring their pivotal role in future vaccine development strategies.

Breakup by Route of Administration:

  • Oral
  • Intramuscular
  • Intranasal
  • Subcutaneous
  • Intradermal
  • Others

Intramuscular represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the route of administration. This includes oral, intramuscular, intranasal, subcutaneous, intradermal, and others. According to the report, intramuscular represented the largest segment.

The intramuscular segment is driven by the increasing demand for vaccines that require deep tissue penetration for optimal efficacy, such as vaccines against influenza, tetanus, and COVID-19. This method is preferred for its ability to deliver larger volumes of a vaccine directly into the muscle, where there is a rich blood supply, facilitating a stronger and quicker immune response. Additionally, the intramuscular route is favored for its relative ease of administration, minimal discomfort, and lower risk of adverse reactions compared to other methods, making it a widely accepted practice in vaccination programs globally. The consistency in vaccine absorption rates and the extensive historical data supporting its effectiveness further bolster its adoption, underlining the segment's growth.

Breakup by Diseases:

  • Cancer
  • Infectious Diseases
  • Others

Infectious diseases accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes cancer, infectious diseases, and others. According to the report, infectious diseases represented the largest segment.

The infectious diseases segment is driven by the increasing prevalence of global pandemics and emerging infectious threats, which highlight the critical need for effective vaccines. Factors such as international travel, urbanization, and climate change contribute to the spread of infectious diseases, necessitating rapid development and deployment of vaccines with potent adjuvants. The segment's growth is further fueled by governmental and international initiatives to combat infectious diseases, alongside significant investments in research and development. Moreover, public awareness and healthcare infrastructure improvements play essential roles in supporting vaccination programs, thereby enhancing the demand for innovative vaccine adjuvants tailored to combat these diseases effectively.

Breakup by Application:

  • Research
  • Commercial

Research represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes research and commercial. According to the report, research represented the largest segment.

The research segment in the vaccine adjuvants market is driven by the increasing demand for more efficacious vaccines against a broader range of pathogens, including emerging and re-emerging infectious diseases. This need is coupled with a growing understanding of the immune system's complexities, prompting scientists to explore novel adjuvant formulations that can elicit stronger and more durable immune responses. Additionally, the push for personalized medicine and vaccines tailored to individual genetic makeups fuels the exploration of innovative adjuvants. Advances in biotechnology and nanotechnology further drive this segment, enabling the development of next-generation adjuvants that can be precisely engineered to enhance vaccine effectiveness while minimizing side effects.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest vaccine adjuvants market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for vaccine adjuvants.

The North America's vaccine adjuvants are expected to dominate the market due to extensive investment in researching and developing (R&D) vaccines that are aimed at tackling a wide range of infectious illnesses and rising health concerns from both the public and private sectors. The region has the advantage of a rapid approval process for vaccines, which encourages drug companies to expand and boost investments into adjuvant technologies. Furthermore, North America has many of the top research centers superiority and frequent collaboration with the biotech sector. As a result, it is the field of medical technology and innovation. In addition, to improve the effectiveness of vaccines, adjuvants, are used with greater awareness of the importance of boosting the effectiveness and safety of vaccines, driving market expansion in North America.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the vaccine adjuvants industry include Adjuvatis, Agenus Inc., Croda International Plc, CSL Limited, Dynavax Technologies, InvivoGen, Novavax Inc., OZ Biosciences, Phibro Animal Health Corporation, SEPPIC, SPI Pharma, etc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players in the vaccine adjuvants market are actively engaging in research and development activities to introduce innovative and more effective adjuvant formulations. These efforts are aimed at enhancing the immune response elicited by vaccines, ensuring broader and more durable protection against a variety of infectious diseases and for therapeutic vaccines targeting chronic conditions such as cancer. For instance, in February 2022, Novavax Inc. announced positive interim results from their Phase 3 clinical trial evaluating their COVID-19 vaccine candidate, NVX-CoV2373, combined with their proprietary adjuvant, Matrix-M. The results showed strong efficacy against COVID-19, demonstrating an overall efficacy of over 90%. Collaborations and partnerships are a common strategy, uniting expertise from academic institutions, research organizations, and biotechnology firms to accelerate the development of next-generation adjuvants. Furthermore, these companies are investing in advanced technologies and exploring novel adjuvant substances, including synthetic molecules and natural compounds, to improve vaccine efficacy and safety profiles. Regulatory compliance and the pursuit of fast-track approval processes are also critical, as companies navigate the complex landscape to bring their innovations to market. Through these actions, key players are significantly contributing to the dynamic growth and evolution of the global vaccine adjuvants market.

Vaccine Adjuvants Market News:

  • In September 2022: Dynavax Technologies embarked on a significant endeavor by commencing a Phase 2 clinical trial for their COVID-19 vaccine candidate, DVX-COV2373. This vaccine, formulated with the company's proprietary adjuvant CpG 1018, represents a promising avenue in the ongoing fight against the COVID-19 pandemic. What distinguishes this trial is its collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI), a global partnership focused on accelerating the development of vaccines against emerging infectious diseases. The primary objective of this Phase 2 trial is to expand upon earlier findings and evaluate DVX-COV2373's safety and efficacy in a larger population. This step is crucial in ensuring that the vaccine meets stringent regulatory standards while also gauging its performance across diverse demographics.
  • In February 2024: CSL (ASX:CSL; USOTC:CSLLY) announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI).

Key Questions Answered in This Report

  • 1. What was the size of the global vaccine adjuvants market in 2023?
  • 2. What is the expected growth rate of the global vaccine adjuvants market during 2024-2032?
  • 3. What are the key factors driving the global vaccine adjuvants market?
  • 4. What has been the impact of COVID-19 on the global vaccine adjuvants market?
  • 5. What is the breakup of the global vaccine adjuvants market based on the product type?
  • 6. What is the breakup of the global vaccine adjuvants market based on route of administration?
  • 7. What is the breakup of the global vaccine adjuvants market based on the diseases?
  • 8. What is the breakup of the global vaccine adjuvants market based on the application?
  • 9. What are the key regions in the global vaccine adjuvants market?
  • 10. Who are the key players/companies in the global vaccine adjuvants market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Adjuvants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Adjuvant Emulsions
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Pathogen Components
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Particulate Adjuvants
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Adjuvants
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intramuscular
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intranasal
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Subcutaneous
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Intradermal
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Diseases

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Infectious Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Research
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Commercial
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Adjuvatis
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Agenus Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Croda International Plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 CSL Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Dynavax Technologies
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 InvivoGen
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Novavax Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 OZ Biosciences
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Phibro Animal Health Corporation
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 SEPPIC
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 SPI Pharma
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Vaccine Adjuvants Market: Major Drivers and Challenges
  • Figure 2: Global: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Vaccine Adjuvants Market: Breakup by Product Type (in %), 2023
  • Figure 5: Global: Vaccine Adjuvants Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Vaccine Adjuvants Market: Breakup by Diseases (in %), 2023
  • Figure 7: Global: Vaccine Adjuvants Market: Breakup by Application (in %), 2023
  • Figure 8: Global: Vaccine Adjuvants Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Vaccine Adjuvants (Adjuvant Emulsions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Vaccine Adjuvants (Pathogen Components) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Vaccine Adjuvants (Pathogen Components) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Vaccine Adjuvants (Particulate Adjuvants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Vaccine Adjuvants (Particulate Adjuvants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Vaccine Adjuvants (Combination Adjuvants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Vaccine Adjuvants (Combination Adjuvants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Vaccine Adjuvants (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Vaccine Adjuvants (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Vaccine Adjuvants (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Vaccine Adjuvants (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Vaccine Adjuvants (Intramuscular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Vaccine Adjuvants (Intramuscular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Vaccine Adjuvants (Intranasal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Vaccine Adjuvants (Intranasal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Vaccine Adjuvants (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Vaccine Adjuvants (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Vaccine Adjuvants (Intradermal) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Vaccine Adjuvants (Intradermal) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Vaccine Adjuvants (Other Routes of Administration) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Vaccine Adjuvants (Other Routes of Administration) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Vaccine Adjuvants (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Vaccine Adjuvants (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Vaccine Adjuvants (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Vaccine Adjuvants (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Vaccine Adjuvants (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Vaccine Adjuvants (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Vaccine Adjuvants (Research) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Vaccine Adjuvants (Research) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Vaccine Adjuvants (Commercial) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Vaccine Adjuvants (Commercial) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: North America: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: North America: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: United States: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: United States: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Canada: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Canada: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Asia-Pacific: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Asia-Pacific: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: China: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: China: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Japan: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Japan: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: India: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: India: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: South Korea: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: South Korea: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Australia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Australia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Indonesia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Indonesia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Europe: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Europe: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Germany: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Germany: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: France: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: France: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: United Kingdom: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: United Kingdom: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Italy: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Italy: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Spain: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Spain: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Russia: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Russia: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Latin America: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Latin America: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Brazil: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Brazil: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Mexico: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Mexico: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Others: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Others: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Middle East and Africa: Vaccine Adjuvants Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Middle East and Africa: Vaccine Adjuvants Market: Breakup by Country (in %), 2023
  • Figure 89: Middle East and Africa: Vaccine Adjuvants Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 90: Global: Vaccine Adjuvants Industry: SWOT Analysis
  • Figure 91: Global: Vaccine Adjuvants Industry: Value Chain Analysis
  • Figure 92: Global: Vaccine Adjuvants Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Vaccine Adjuvants Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Vaccine Adjuvants Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 3: Global: Vaccine Adjuvants Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Vaccine Adjuvants Market Forecast: Breakup by Diseases (in Million US$), 2024-2032
  • Table 5: Global: Vaccine Adjuvants Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 6: Global: Vaccine Adjuvants Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Vaccine Adjuvants Market: Competitive Structure
  • Table 8: Global: Vaccine Adjuvants Market: Key Players